Comparative Pharmacology
Head-to-head clinical analysis: ANNOVERA versus ASHLYNA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANNOVERA versus ASHLYNA.
ANNOVERA vs ASHLYNA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive containing segesterone acetate, a progestin, and ethinyl estradiol, an estrogen. Segesterone acetate suppresses gonadotropin release, preventing ovulation; ethinyl estradiol contributes to contraceptive efficacy by stabilizing the endometrium and inhibiting gonadotropin secretion.
ASHLYNA is a combination of ethinyl estradiol and drospirenone. The contraceptive effect is based on inhibition of ovulation and alterations in cervical mucus and endometrial receptivity. Drospirenone has antimineralocorticoid and antiandrogenic activity.
One vaginal ring inserted and left in place for 3 weeks, followed by a 1-week ring-free interval. Each ring releases ethinyl estradiol 0.024 mg/day and segesterone acetate 0.15 mg/day over 21 days.
One tablet (0.02 mg ethinyl estradiol / 3 mg drospirenone) orally once daily for 21 days, followed by 7 placebo tablets.
None Documented
None Documented
Terminal half-life of etonogestrel (ENG): ~25 hours; ethinylestradiol (EE): ~12 hours; steady-state achieved after 7-14 days.
Terminal half-life: 12–15 hours; clinical context: supports once-daily dosing
Renal: ~60% as metabolites; fecal: ~35% as metabolites; biliary: minor.
Renal: ~60% unchanged; fecal: ~30% (metabolites); biliary: ~10%
Category C
Category C
Contraceptive
Contraceptive